Forbion
FRBN
Performance
About Forbion
Forbion is a leading venture capital firm that works closely with entrepreneurs to build life sciences companies that transform people's lives.
Recent News
Corsera Health Raises $80M in Series A Financing
Protego Biopharma Lands $130 Million Oversubscribed Series B Financing
Seven Biotech Companies to Know in the Netherlands
Gate Bioscience Raises $65M in Series B Financing
Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement
CellCentric Initiates DOMMINO-1, a Pivotal Phase 2 Clinical Trial of Inobrodib in Combination with Pomalidomide and Dexamethasone (InoPd) in Relapsed or Refractory Multiple Myeloma
Lilly, Seamless Ink Up-to-$1.12B Hearing Loss Collaboration
Protego Biopharma Raises $130M in Series B Financing
Recent Deals
Protego Biopharma Secures $130M Series B Funding
Corsera Health Secures $80M Series A Funding Led by Forbion and Population Health Partners
Gate Bioscience Secures $65M Series B Round Led by Forbion and Eli Lilly
Protego Biopharma Secures $130M Series B Funding Led by Novartis Venture Fund
Elevara Medicines Raises $70M Series A to Advance RA and Inflammatory Disease Program
Slate Medicines Secures $130M Series A Funding Led by RA Capital, Forbion and Foresite Capital
Expedition Therapeutics Raises $165M Series A Led by Sofinnova Investments and Novo Holdings
Corsera Raises $80M as First Preventative Heart Disease Program Moves Into Clinic
